Article · Wikipedia archive · Last revised Jul 10, 2026

Lavoltidine

Lavoltidine (INN, USAN, BAN; previously known as loxtidine; development code AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline) as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.

Last revised
Jul 10, 2026
Read time
≈ 1 min
Length
163 w
Citations
4
Source
Wikipedia ↗
Lavoltidine
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • Development terminated
Identifiers
  • [1-methyl-5-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1,2,4-triazol-3-yl]methanol
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H29N5O2
Molar mass359.474 g·mol−1
3D model (JSmol)
  • OCc1nn(C)c(n1)NCCCOc2cccc(c2)CN3CCCCC3

Lavoltidine (INN,1 USAN, BAN; previously known as loxtidine; development code AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline)2 as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.34

See also

See also

References

References

  1. "International Nonproprietary Names for Pharmaceutical Substances. Recommended International Nonproprietary Names (Rec. INN): List 30" (PDF). WHO Drug Information. 4 (3). World Health Organization: 7. 1990. Retrieved 12 January 2016.
  2. "Drug Profile: Lavoltidine". AdisInsight. Springer International Publishing AG. Retrieved 12 January 2016.
  3. Washington N (1991). Antacids and anti-reflux agents. Boca Raton: CRC Press. ISBN 0-8493-5444-7.
  4. Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8.